AmideBio
- Company typePrivate
- Founded2009
- HeadquartersLouisville, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
AmideBio firmographics
Firmographics- Name
- AmideBio
- Legal name
- AmideBio, LLC
- Website
- https://AmideBio.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
AmideBio industry classification
Industry- Product category
- Peptide Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where AmideBio is headquartered
LocationHeadquarters
- HQ city
- Louisville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AmideBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Drug Development Pipeline: Developing proprietary peptide therapeutics targeting metabolic diseases including diabetes and hypoglycemia, with candidate drugs advancing through preclinical and clinical stages.
- Custom Peptide Synthesis Services: Provides custom synthesis services and a portfolio of peptides to customers seeking high purity, low cost solutions.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
AmideBio product offering
Product offeringCore offering
AmideBio develops and commercializes peptide-based products through two complementary lines: (1) custom peptide synthesis services and an off-the-shelf peptide catalog sold to pharmaceutical, biotechnology, and research customers seeking high-purity, cost-effective peptides; and (2) an internal drug discovery pipeline of peptide drug candidates targeting metabolic diseases, including a dual agonist insulin for impaired awareness of hypoglycemia and a long-acting glucagon analog for hyperinsulinism.
Product overview
AmideBio is a biopharmaceutical company offering a combination of peptide synthesis services and an internal drug discovery pipeline. The company provides custom synthesis services and a catalog of off-the-shelf peptides for customers seeking high purity, low cost solutions. Simultaneously, AmideBio leverages its in-silico design and proprietary peptide synthesis capabilities to develop a pipeline of unique peptide drug candidates targeting metabolic disease, including dual agonist insulin and long-acting glucagon analog candidates.
Differentiator
Problem solved
Functional benefit
Products and services
- Custom Peptide Synthesis Services High-purity, low-cost custom peptide synthesis services provided to pharmaceutical companies, biotechnology firms, and research laboratories seeking tailored peptide solutions via direct email or phone inquiry.
- Peptide Catalog Online catalog of off-the-shelf peptides available for purchase by researchers and laboratories seeking high-purity, cost-effective peptide solutions.
- Drug Discovery Pipeline (Metabolic Disease Peptide Candidates) Proprietary pipeline of peptide drug candidates targeting metabolic diseases, including dual agonist insulin for impaired awareness of hypoglycemia (IAH) and long-acting glucagon analog for hyperinsulinism. Developed for out-licensing or co-development to pharmaceutical partners.
Companies that use AmideBio
Customer profileSegments2 records
Ideal customer profiles2 records
AmideBio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
AmideBio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Children's Hospital of Philadelphia (CHOP)coreDr. Diva D. De León-Crutchlow at CHOP is involved in the pre-clinical development of AmideBio's long-acting glucagon analog for treating hyperinsulinism. This collaboration supports the company's IND filing with the FDA.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
AmideBio competitors and assessment
Company assessmentDirect peers
- Zealand Pharma: Zealand Pharma is a clinical-stage peptide therapeutics company developing engineered peptides for metabolic and rare diseases, with programs in hypoglycemia and hyperinsulinism-adjacent indications. It is the closest pure-play comparable to AmideBio's peptide drug development model targeting similar endocrine indications.
- Bachem: Bachem is a leading peptide CDMO offering custom synthesis, catalog peptides, and API manufacturing for pharmaceutical and research customers worldwide. AmideBio's custom synthesis and catalog peptide business maps directly to Bachem's commercial offering.
- PolyPeptide Group: PolyPeptide Group manufactures custom and catalog peptides for pharma and research clients, operating a similar service-plus-molecules business model. Both companies serve as peptide synthesis partners to drug developers, making them direct commercial comparables.
Broad incumbents
- Novo Nordisk: Novo Nordisk is the dominant incumbent in peptide therapeutics for diabetes, hypoglycemia, and obesity, with GLP-1, insulin, and glucagon franchises. AmideBio's metabolic targets sit directly within Novo Nordisk's core franchise, positioning it as either competitor or acquisition/licensing target.
- Eli Lilly: Eli Lilly is a leading metabolic disease pharmaceutical company with major peptide (GLP-1) and insulin franchises. Its cardiometabolic focus and active business development in next-generation peptides make it a logical potential partner or competitor for AmideBio.
Emerging players
- PeptiDream: PeptiDream operates a proprietary peptide discovery platform and partners with major pharma on peptide therapeutics across multiple indications including metabolic disease. The platform's discovery-plus-partnership business model parallels AmideBio's approach.
- Crinetics Pharmaceuticals: Crinetics develops peptide therapeutics targeting endocrine diseases and rare endocrine disorders. Its focus on peptide drugs for unmet needs in endocrinology is highly aligned with AmideBio's therapeutic area strategy.
- Carmot Therapeutics: Carmot Therapeutics (acquired by Roche) developed peptide and small-molecule therapeutics for metabolic diseases including diabetes and obesity. Its dual focus on novel peptide design and metabolic disease makes it a thematic comparable to AmideBio's pipeline.
- Structure Therapeutics: Structure Therapeutics is a clinical-stage company developing oral and injectable peptide mimetics for metabolic and cardiovascular disease. It overlaps with AmideBio on peptide design philosophy and cardiometabolic focus, though at a more advanced clinical stage.
Others
- GenScript: GenScript provides custom peptide synthesis, gene synthesis, and biologics services to researchers and biotech companies. Its peptide services business directly overlaps with AmideBio's custom synthesis service line in target customer and technology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
AmideBio social profiles
Digital presenceAmideBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
AmideBio leadership team
Management profileNumber of profiles
Profiles3 records
AmideBio funding detail
Funding detailFunding overview
Funding rounds8 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AmideBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AmideBio
What does AmideBio do?
AmideBio develops and commercializes peptide-based products through two complementary lines: (1) custom peptide synthesis services and an off-the-shelf peptide catalog sold to pharmaceutical, biotechnology, and research customers seeking high-purity, cost-effective peptides; and (2) an internal drug discovery pipeline of peptide drug candidates targeting metabolic diseases, including a dual agonist insulin for impaired awareness of hypoglycemia and a long-acting glucagon analog for hyperinsulinism.
Is AmideBio a public or private company?
AmideBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AmideBio founded?
AmideBio was founded in 2009. It employs 1 to 10 people.
Where is AmideBio based?
AmideBio is headquartered in Louisville, United States, in the North America region.
How does AmideBio make money?
Two revenue lines are on record. Drug Development Pipeline is the primary driver. The others are custom Peptide Synthesis Services.
Who are AmideBio's main competitors?
Direct peers on record are Zealand Pharma, Bachem and PolyPeptide Group. Broad incumbents are Novo Nordisk and Eli Lilly. Emerging players are PeptiDream, Crinetics Pharmaceuticals, Carmot Therapeutics and Structure Therapeutics. GenScript is listed as an others.
Does AmideBio have an API?
No public API is recorded for AmideBio.
What industry is AmideBio in?
AmideBio's product category is Peptide Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325414 and its SIC code is 2834.